What is Intrahepatic Cholangiocarcinoma? Intrahepatic cholangiocarcinoma (ICC) is a rare type of cancer that forms in the bile ducts within the liver. The bile ducts are thin tubes that carry bile from the liver to the gallbladder and small intestine. Bile is a fluid that is made by the liver to help break down and absorb fat and fat-soluble vitamins. ICC begins when healthy bile duct cells become malignant (cancerous) and start to multiply uncontrollably, forming tumors within the liver. Because these cancers arise from bile duct cells inside the liver, they are called "intrahepatic" cholangiocarcinomas. Risk Factors and Causes While the exact causes of intrahepatic cholangiocarcinoma are unclear, several risk factors are associated with its development: - Liver flukes: In areas of Southeast Asia and parts of South America, infection with the parasitic liver fluke Opisthorchis viverrini or Clonorchis sinensis is a major risk factor. These flukes can cause chronic inflammation and damage to the bile ducts over time. - Primary sclerosing cholangitis (PSC): PSC is a chronic inflammatory disease of the bile ducts that can predispose individuals to developing ICC. Approximately 5-10% of people with PSC will develop ICC within 10-15 years. - Liver cirrhosis: Cirrhosis, or severe scarring of the liver from any cause (hepatitis, alcohol, non-alcoholic fatty liver disease) increases the risk of ICC. - Metabolic disorders: Conditions like obesity, diabetes, metabolic syndrome are linked to a higher ICC incidence. - Toxic exposures: Long-term exposure to thorium dioxide, polychlorinated biphenyls, and dioxin contaminants elevates ICC risk. Signs and Symptoms In the early stages, intrahepatic cholangiocarcinoma often does not cause signs or symptoms. As the cancer grows, patients may experience: - Fatigue and weakness - Loss of appetite and unintentional weight loss - Abdominal pain or discomfort on the right upper side of the abdomen - Jaundice (yellowing of the skin and eyes) due to bile duct blockage - Light-colored stools and dark urine - Fever - Itching - Nausea and vomiting Diagnosis If symptoms suggest ICC, the doctor will conduct a physical exam and evaluate the patient's medical history. Diagnostic tests used to detect or rule out ICC include: - Blood tests - Liver and bile duct function tests may indicate blockage or damage. Tumor marker tests like CA19-9 are often elevated. - Ultrasound - Used to view the liver, gallbladder, and bile ducts for abnormalities. - CT or MRI scan - Provides highly detailed images of the liver and bile ducts. - Liver biopsy - A small sample of the abnormal tissue is removed and examined under a microscope to confirm ICC. - Endoscopic ultrasound - A probe is inserted through the mouth to ultrasound the bile ducts from inside the body. Useful for biopsies. Staging and Grading If intrahepatic cholangiocarcinoma is diagnosed, additional tests help determine the stage (extent) of the cancer: - Stage I - Tumor is only in the liver. - Stage II - Tumor has spread within the liver. - Stage III - Tumor has spread to lymph nodes near the liver or adjacent organs. - Stage IV - Cancer has spread to other distant organs. The grade indicates how fast the cancer may grow and spread: - Well differentiated: Looks more like normal tissue, tends to grow and spread more slowly. - Moderately differentiated: Looks somewhat like normal tissue, average behavior. - Poorly differentiated: Looks very abnormal, tends to grow and spread more quickly. Treatment and Prognosis Treatment for Intrahepatic cholangiocarcinoma depends on the stage and grade at diagnosis. For early stage ICC, surgery to remove all or part of the liver (partial hepatectomy or liver transplant) offers the best chance of a cure. But most ICC is advanced at diagnosis. For unresectable liver tumors, minimally invasive ablation techniques using radiofrequency energy, alcohol, or cryotherapy can destroy cancer cells. Chemotherapy like gemcitabine plus cisplatin may stop tumor growth and help with symptoms for some period. Targeted drugs like bevacizumab that block angiogenesis are also options. Unfortunately, ICC is a difficult cancer to treat as it often recurs even after successful treatment. The overall 5-year survival rate is only 10-30% for resected ICC. For unresectable disease, the 5-year rate is even lower at 5%. Liver transplantation provides the best outcome, with 5-year survival up to 50-70% depending on tumor factors. Prevention and Outlook Currently there are no established prevention strategies for ICC given the uncertain causes in most cases. Those at highest risk like PSC and liver fluke patients should get regular surveillance screening. Leading a healthy lifestyle to prevent liver diseases may help lower Intrahepatic cholangiocarcinoma chances indirectly. While the prognosis remains guarded, ongoing research into early detection methods and new targeted therapies promise hope for improved ICC survival rates in the future. Heightened global awareness could also aid efforts to curb risk factors and curb the rising incidence internationally. Until then, receiving a prompt diagnosis and coordinated treatment from a specialized hepatobiliary team offers patients the best chance against this aggressive cancer.
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163
*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it
Ovarian cancer is known as the disease that whispers, but it is NOT whispering.
It IS SPEAKING to us, we just are not listening.
And it’s time that we did.
It’s time to bring significant efforts and energy to solving for this devastating disease, Aspira Women’s Health is the company to do just that.
DelveInsight's Adrenal Cortex Neoplasms Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Adrenal Cortex Neoplasms, historical and forecasted epidemiology as well as the Adrenal Cortex Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Adrenal Cortex Neoplasms is rare cancer that originates in the outer layer of the adrenal gland.
A tumor of the adrenal cortex may be functioning (produces surplus hormones than usual) or nonfunctioning (does not produce surplus hormones than usual).
Most adrenocortical tumors are functioning.Some facts of Adrenal Cortex Neoplasms Market are:Adrenal Cortex Neoplasms is a rare malignancy with poor prognosis.
It occurs at any age, with two peak incidence: the first in the first decade and the second between 40‒50 years.In the retrospective review conducted by Wang et al.
titled “Prognostic Factors of Adrenal Cortex Neoplasms: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database,” the study population of Adrenal Cortex Neoplasms consist of 60.6% females and 39.4% males.
titled “How is Adrenocortical Cancer being Managed in the UK?,” the incidence of Adrenal Cortex Neoplasms is 0.5‒2 per million per year.According to the study by Johanssen et al.
